AnnouncementsHikal completes EDQM audit at its Bangalore facility
52 Week HighHikal has hit a 52wk high of Rs 673.00 on NSE
52 Week HighHikal has hit a 52wk high of Rs 611.75 on NSE
52 Week HighHikal has hit a 52wk high of Rs 558.00 on NSE
AnnouncementsHikal recommends dividend
100% of moneycontrol users recommend selling Hikal.
What's your call on Hikal today?
Read 1 investor views
|Company Name||Last Price||%
|Dr Reddys Labs||2995.60||0.48||3000.00||2286.80||51,025.56|
|Dec' 13||Sep' 13||Jun' 13||Mar' 13|
IFGL Refractories Recommended on May 28th 2014
Recommended price 114.00 | Peak from reco 209.00 83.01%
What are Multi baggers?
Our experts panel will help you to get you those life-changing stocks, tomorrow's bluechips today.
Hikal is in the Pharmaceuticals sector. The current market capitalisation stands at Rs 1,000.22 crore.The company has reported a standalone sales of Rs 190.39 crore and a Net Profit of Rs 5.70 crore for the quarter ended Jun 2014.
The company management includes Jai Hiremath - Chairman & Managing Director, Sameer Hiremath - Joint Managing Director, Baba Kalyani - Director, Prakash Mehta - Director, Shivkumar Kheny - Director, Kannan Unni - Director, Peter Pollak - Director, Amit Kalyani - Director, Wolfgang Welter - Director, Sugandha Hiremath - Director, C G Kumar - Independent Director, Suguna Ravichandran - Independent Director, Axel Kleemann - Additional Director.
It is listed on the BSE with a BSE Code of 524735 and the NSE with an NSE Code of HIKAL.
Its Registered office is at 717/718, Maker Chambers V,,Nariman Point Mumbai,Maharashtra - 400021.
Their Registrars are Universal Capital Securities Pvt. Ltd.